Biomarin Pharmaceutical (BMRN) Assets Average (2010 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Assets Average came in at $8.1 billion in Q1 2026, up 14.5% YoY from $7.1 billion in Q1 2025, and up 6.42% on a QoQ basis from $7.6 billion in Q4 2025.
Biomarin Pharmaceutical (BMRN) Assets Average (2010 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 17 years of Assets Average data on file, last reported at $8.1 billion in Q1 2026.
- Quarterly Assets Average rose 14.5% year-over-year to $8.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 billion (up 14.5% YoY) and the FY2025 annual result came in at $7.3 billion, up 5.44% from the prior year.
- Assets Average climbed to $8.1 billion in Q1 2026, from $7.6 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $8.1 billion in Q1 2026 to a low of $6.0 billion in Q1 2022.
- A 5-year average of $6.8 billion and a median of $6.9 billion in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average climbed 1.77% — and 2026, when it advanced 14.5%.
- Tracing BMRN's Assets Average over 5 years: stood at $6.3 billion in 2022, then climbed by 7.6% to $6.8 billion in 2023, then rose by 1.77% to $6.9 billion in 2024, then gained by 9.89% to $7.6 billion in 2025, then increased by 6.42% to $8.1 billion in 2026.
- The last three Assets Average figures came in at $8.1 billion (Q1 2026), $7.6 billion (Q4 2025), and $7.5 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 10.16 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.16 Bn |
| Mar 31, 2026 | 8.09 Bn |
| Dec 31, 2025 | 7.60 Bn |
| Sep 30, 2025 | 7.54 Bn |
| Jun 30, 2025 | 7.30 Bn |
| Mar 31, 2025 | 7.07 Bn |
| Dec 31, 2024 | 6.92 Bn |
| Sep 30, 2024 | 6.96 Bn |
| Jun 30, 2024 | 6.97 Bn |
| Mar 31, 2024 | 6.86 Bn |
| Dec 31, 2023 | 6.80 Bn |
| Sep 30, 2023 | 6.66 Bn |
| Jun 30, 2023 | 6.50 Bn |
| Mar 31, 2023 | 6.40 Bn |
| Dec 31, 2022 | 6.32 Bn |
| Sep 30, 2022 | 6.20 Bn |
| Jun 30, 2022 | 6.10 Bn |
| Mar 31, 2022 | 6.03 Bn |
| Dec 31, 2021 | 5.99 Bn |
| Sep 30, 2021 | 5.94 Bn |